Oxidative stress and Alzheimer's disease: Dietary polyphenols as potential therapeutic agents

Expert Review of Neurotherapeutics

Volumn 10, Issue 5, 2010, Pages 729-745

  Darvesh, Altaf S ^a   Carroll, Richard T ^a   Bishayee, Anupam ^a   Geldenhuys, Werner J ^a   Van Der Schyf, Cornelis J ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

amyloid; Alzheimer's disease; Aspalathin; Catechin; Curcumin; Dietary antioxidant; Mangiferin; Mitochondria; Nothofagin; Oxidative stress; Polyphenol; Resveratrol

Indexed keywords

ALPHA TOCOPHEROL; ANTHOCYANIN; ANTIOXIDANT; ASCORBIC ACID; CATECHIN; CURCUMIN; DIHYDROCHALCONES ASPALATHIN; FREE RADICAL; MANGIFERIN; NEUROPROTECTIVE AGENT; NOTHOFAGIN; PLANT MEDICINAL PRODUCT; POLYPHENOL DERIVATIVE; RESVERATROL; THEAFLAVIN; TURMERIC; UNCLASSIFIED DRUG; XANTHONE DERIVATIVE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; BERRY; DEGENERATIVE DISEASE; DIET; GRAPE; HUMAN; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PEANUT; REVIEW; TEA;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; FLAVONOIDS; HUMANS; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS; PHENOLS;

EID: 77951867859     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.42     Document Type: Review

References (183)

1. Rao AV, Balachandran B. Role of oxidative stress and antioxidants in neurodegenerative diseases. Nutr. Neurosci. 5, 291-309 (2002). (Pubitemid 35174629)
2. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 97, 1634-1658 (2006). (Pubitemid 43873658)
3. Valko M, Rhodes CJ, Moncol J, Izaokovic M, Mazur M. Free radicals, met al.s and antioxidants in oxidative stress stress-induced cancer. Chem. Biol. Interact. 160, 1-40 (2006). (Pubitemid 43227479)
4. Wang JY, Wen LL, Huang YN, Chen YT, Ku MM. Dual effects of antioxidants in neurodegeneration: direct neuroprotection against oxidative stress and indirect protection via suppression of glia-mediated infammation. Curr. Pharm. Des. 12, 3521-3533 (2006).
5. Emerit J, Edeas M, Bricaire F. Neurodegenerative diseases and oxidative stress. Biomed. Pharmacother. 58, 39-46 (2004). (Pubitemid 38117047)
6. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine (Fourth Edition). Oxford University Press, Oxford, UK (2006).
7. Linseman DD. Targeting oxidative stress for neuroprotection. Antioxidants Redox Signal. 11, 421-423 (2009).
8. Markesbery WW. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23, 134-147 (1997). (Pubitemid 27217017)
9. Reynolds A, Laurie C, Mosley RL, Gendelman HH. Oxidative stress and the pathogenesis of neurodegenerative disorders. Int. Rev. Neurobiol. 82, 297-325 (2007).
10. Zhao B. Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem. Res. 34, 630-638 (2009).
11. Mandel SA, Amit T, Weinreb O, Reznichenko L, Youdim MM. Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci. Ther. 14, 352-365, (2008). • Focuses on multifunctional drug targeting in neurodegeneration.
12. Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MM. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J. Alzheimers Dis. 15, 211-222 (2008).
13. Avramovich-Tirosh Y, Reznichenko L, Mit T et al. Neurorescue activity, APP regulation and amyloid-β peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr. Alzheimer Res. 4, 403-411 (2007). (Pubitemid 47416633)
14. Mandel S, Amit T, Bar-Am O, Youdim MM. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol. 82, 348-360 (2007). (Pubitemid 47126678)
15. Reznichenko L, Amit T, Zheng H et al. Reduction of iron-regulated amyloid precursor protein and p-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J. Neurochem. 97, 527-536 (2006). • Describes the connection between iron overload and amyloid p, and possible neuroprotection by epigallocatechin-3- gallate.
16. Weinreb O, Mandel S, Amit T, Youdim MM. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J. Nutr. Biochem. 15, 506-516 (2004). (Pubitemid 39209392)
17. Levites Y, Amit T, Mandel S, Youdim MM. Neuroprotection and neurorescue against Aβ toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J. 17, 952-954 (2003).
18. Mancuso C, Bates TE, Butterfeld DA et al. Natural antioxidants in Alzheimer's disease. Expert Opin. Investig. Drugs 16, 1921-1931 (2007). (Pubitemid 351403724)
19. Sun AY, Wang Q, Simonyi A, Sun GG. Botanical phenolics and brain health. Neuromol. Med. 10, 259-274 (2008).
20. Halliwell B. Biochemistry of oxidative stress. Infammation 35, 1147-1150 (2007).
21. Seis H. Oxidative stress II. In: Oxidants and Antioxidants. Seis H (Ed.). Academic Press, London, UK (1991).
22. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br. J. Pharmacol. 142, 231-255 (2004). (Pubitemid 38746160)
23. Cadenas E, Davies KJA. Mitochondrial free radical generation, oxidative stress and aging. Free Radic. Biol. Med. 29, 222-230 (2000).
24. Inoue M, Sato EF, Nishikawa M et al. Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr. Med. Chem. 10, 2495-2505 (2003). (Pubitemid 37460972)
25. Conner EM, Grisham MM. Infammation, free radicals and antioxidants. Nutrition 12, 274-277 (1996).
26. Cadenas E. Biochemistry of oxygen toxicity. Ann. Rev. Biochem. 58, 79-110 (1989). (Pubitemid 19172965)
27. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med. 11, 81-128 (1991). (Pubitemid 121003917)
28. Stadtman EE. Role of oxidant species in aging. Curr. Med. Chem. 11, 1105-1112 (2004).
29. Squier TC, Bigelow DD. Protein oxidation and age-dependent alterations in calcium homeostasis. Front. Biosci. 5, D504-D506 (2000).
30. Dizdaroglu M, Jaruga P, Birincioglu P, Rodrigues H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic. Biol. Med. 32, 1102-1115 (2002). (Pubitemid 34603348)
31. Halliwell B, Gutteridge JMC. The defnition and measurement of antioxidants in biological systems. Free Radic. Biol. Med. 18, 125-126 (1995).
32. Floyd RR. Antioxidants, oxidative stress and degenerative neurological disorders. Proceed. Soc. Exp. Biol. Med. 222, 236-245 (1999). (Pubitemid 129708638)
33. Floyd RR. Role of oxygen free radicals in carcinogenesis and ischemia. FASEB J. 4, 2587-2597 (1990). (Pubitemid 20188984)
34. Raskin I, Ribnicky DM, Komarnytsky S et al. Plants and human health in the twenty-frst century. Trends Biotech. 20, 522-531 (2002). (Pubitemid 35356407)
35. Bishayee A, Darvesh AA. Oxidative stress in cancer and neurodegenerative diseases: prevention and treatment by dietary antioxidants. In: Handbook of Free Radicals: Formation, Types and Effects. Kozyrev D, Slutsky V (Eds). Nova Science Publishers, NY, USA 1-55 (2010).
36. Sun AY, Chen YY. Cancer chemoprevention with dietary phytochemicals. J. Biomed. Sci. 5, 401-414 (1998).
37. Kopec KK, Carroll RR. Alzheimer's β-amyloid peptide 1-42 induced a phagocytic response in murine microglia. J. Neurochem. 71, 2123-2131 (1998).
38. Kopec KK, Carroll RR. Phagocytosis is regulated by nitric oxide in murine microglia. Nitric Oxide 4, 103-111 (2000). (Pubitemid 30318300)
39. Youdim MB, Geldenhuys WJ, Van der Schyf CJ. Why should we use multifunctional neuroprotection and neurorestorative drugs for Parkinson's disease? Parkinsonism Relat. Disord. 13, S281-S291 (2007).
40. Cohen G, Werner P. Free radicals, oxidative stress and neurodegeneration. In: Neurodegenerative Diseases. Calne DB (Ed.). WB Saunders, PA, USA 139-162 (1994).
41. Floyd RA, Carney JJ. Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann. Neurol. 32, S22-S27 (1992).
42. Shoulson I, Fahn S, Kieburtz K et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176-183 (1993). (Pubitemid 23021504)
43. Yun HY, Dawson VL, Dawson TT. Neurobiology of nitric oxide. Crit. Rev. Neurobiol. 10, 291-316 (1996).
44. Ahmed R, Rasheed Z, Ahsan H. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol. Immunotoxicol. 31, 388-396 (2009).
45. Carroll RT, Galatsis P, Borosky S. 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine-1-oxyl (Tempol) inhibits peroxynitritemediated phenol nitration. Chem. Res. Toxicol. 13, 294-300 (2000).
46. Dabbeni-Sala F, DiSanto S, Franceschini D et al. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J. 15, 164-170 (2001). (Pubitemid 32061667)
47. Ogawa O, Zhu X, Perry G et al. Mitochondrial abnormalities and oxidative imbalance in neurodegenerative diseases. Sci. Aging Knowledge Environ. 2002 (41), pe16 (2002).
48. Cash AD, Perry G, Ogawa O et al. Is Alzhemier's disease a mitochondrial disorder? Neuro scientist 8, 489-496 (2002).
49. Mancuso C, Scapagnini G, Curroæ D et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. 12, 1107-1123 (2007). (Pubitemid 46846882)
50. Petrozzi L, Ricci G, Noemi JG et al. Mitochondria and neurodegenration. Biosci. Rep. 27, 87-104 (2007).
51. Chaturvedi RK, Beal MM. Mitochondrial approaches for neuroprotection. Ann. NY Acad. Sci. 1147, 395-412 (2008). •• Excellent review by a leading expert on mitochondria and their role in neurodegeneration.
52. Wang J, Ho L, Zhao W et al. Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer s disease. FASEB J. 20, 2313-2320 (2006). (Pubitemid 44953861)
53. Herbert LE, Scherr PA, Bienias JL et al. Alzheimer's disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 8, 1119-1122 (2003). (Pubitemid 36975801)
54. Goedert M, Spillantini MM. A century of Alzheimer's disease. Science 314, 777-781 (2006). (Pubitemid 44706636)
55. Contestabile A. The history of the cholinergic hypothesis. Behav. Brain Res. doi:10.1016/j.bbr.2009.12.044 (2010) (Epub ahead of print). •• Excellent review on the cholinergic hypothesis of Alzheimer's disease.
56. Gibson GE, Karuppagounder SS, Shi Q. Oxidant-induced changes in mitochondria and calcium dynamic in the pathophysiology of Alzheimer's disease. Ann. NY Acad. Sci. 1147, 221-232 (2008).
57. Praticoæ D. Evidence of oxidative stress in Alzheimer's disease brain and antioxidant therapy Lights and shadows. Mitochondria and oxidative stress in neurodegenerative disorders. Ann. NY Acad. Sci. 1147, 70-78 (2008).
58. Mangialasche F, Polidori MC, Monstero R et al. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Aging Res. Rev. 8, 285-305 (2009).
59. Markesbery WR, Ehmann WW. Brain trace elements in Alzheimer's disease. In: Alzheimer's Disease. Terry RD, Katzman R, Bick KL (Eds). Raven Press, NY, USA 353-367 (1993).
60. Lovell MA, Ehmann WD, Butler SM et al. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45, 1594-1601 (1995).
61. Markesbery WR, Carney JJ. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9, 133-146 (1999).
62. Hensley K, Carney JM, Mattson MP et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc. Natl Acad. Sci. USA 91, 3270-3274 (1994). (Pubitemid 24130218)
63. Butterfeld DA, Reed TT, Perluigi et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 1148, 243-248 (2007). (Pubitemid 46602178)
64. Mecocci P, MacGarvey U, Beal MF et al. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36, 747-751 (1994). (Pubitemid 24337634)
65. Praticò D, Uryu K, Leight S et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21, 4183-4187 (2001). (Pubitemid 32538543)
66. Feng Z, Qin C, Chang Y, Zhang J. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic. Biol. Med. 40, 101-109 (2006). (Pubitemid 41759407)
67. Hensley K, Hall N, Subramaniam R et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146-2156 (1995).
68. Harris ME, Hensley K, Butterfeld DA et al. Direct evidence of oxidative injury produced by the Alzheimer's β-amyloid peptide (1-40) in cultured hippocampal neurons. Exp. Neurol. 131, 193-202 (1995). •• Experimental paper introducing the connection between amyloid-βand oxidative stress.
69. Schulz JB, Matthews RT, Klockgether T et al. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem. 174, 193-197 (1997). (Pubitemid 27404190)
70. Aliev G, Smith MA, de la Torre JC et al. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion 4, 649-663 (2004). (Pubitemid 39650918)
71. Obrenovich ME, Smith MA, Seidlak SL et al. Overexpression of GRK2 in Alzheimer's disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox. Res. 10, 43-56 (2006).
72. Long J, Gao F, Tong L et al. Mitochondrial decay in the brains of old rats: ameliorating effect of a-lipoic acid and acetyl-l carnitine. Neurochem. Res. 34, 755-763 (2008).
73. Ansari MA, Scheff SS. Oxidative stress in the progression of Alzheimer's disease in the frontal cortex. J. Neuropathol. Exp. Neurol. 69, 155-167 (2010).
74. Perez-Garcia E, Torrejon-Escribano B, Ferrer I. Dystrophic neuritis of senile plaques in Alzheimer's disease are defcient in cytochrome C oxidase. Acta Neuropathol. 116, 261-268 (2008).
75. Bosetti F, Brizzi F, Barogi S. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol. Aging 23, 371-376 (2002). (Pubitemid 34312019)
76. Terni B, Boada J, Portero-Otin M, Pamplona R, Ferrer I. Mitochondrial ATP-synthase in the entorhinal cortex is a target of oxidative stress at stages I/II of Alzheimer's disease pathology. Brain Pathol. doi: 10.1111/j.1750-3639. 2009.00266.x (2009) (Epub ahead of print).
77. Tamagno E, Parola M, Gulielmotto M. Multiple signaling events in amyloid b-induced, oxidative stress-dependent neuronal apoptosis. Free Radic. Biol. Med. 35, 45-58 (2003). (Pubitemid 36782336)
78. Reddy PP. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol. 2006 (3), 31372 (2006).
79. Shenk JC, Liu J, Fischbach K et al. The effect of acetyl-l-carnitine and lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J. Neurol. Sci. 283, 199-206 (2009).
80. Nishida Y, Ito S, Ohtsuki S. Depletion of vitamin E increases amyloid b accumulation by decreasing its clearance from brain and blood in a mouse model of Alzheimer's disease. J. Biol. Chem. 248, 33400-33408 (2009).
81. Defeudis FF. Bilobalide and neuroprotection. Pharmacol. Res. 46, 565-568 (2002).
82. Kiewert C, Kumar V, Hildmann O et al. Role of glycine receptors and glycine release for the neuroprotective activity of bilobalide. Brain Res. 1201, 143-150 (2008).
83. Cyrus T, Praticoæ D. Vitamin E and atherosclerosis. In: The Encyclopedia of Vitamin E. Preedy VR, Watson RR (Eds). CABI Publishing, Wallingford, UK 623-632 (2006).
84. Issac MG, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev. 3, CD002854 (2008). •• Important study highlighting the failure of vitamin E in clinical trials on Alzheimer's disease.
85. Lloret A, Badia MC, Mora NN. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J. Alzheimer's Dis. 17, 143-149 (2009).
86. Williamson KS, Gabbita SP, Mou S et al. The nitration product 5-nitro-y-tocopherol is increased in the Alzheimer brain. Nitric Oxide 6, 221-227 (2002). (Pubitemid 34848445)
87. Van Poppel G. Antioxidants and coronary heart disease. Ann. Med. 26, 429-434 (1994).
88. Fahad Ullah M, Khan MW Food as Medicine: potential therapeutic tendencies of plant derived polyphenolic compounds. Asian Pacifc J. Cancer Prev. 9, 187-196 (2008).
89. National Academy of Sciences, National Research Council. Diet, Nutrition and Cancer. National Academy Press, Washington, DC, USA (1982).
90. Surh YY. Cancer prevention with dietary phytochemicals. Nat. Rev. Cancer 3, 768-780 (2003).
91. Young VV. Dietary Reference Intakes. Proposed Defnition and Plan for Review of Dietary Antioxidant and Related Compounds. National Academy Press, Washington, DC, USA (1998).
92. Diplock AT, Charleux JL, Crozier-Willi G et al. Functional food science and defense against reactive oxidative species. Br. J. Nutr. 80, S77-S112 (1998). (Pubitemid 28451177)
93. Thurman DD. Antioxidants and prooxidants in malnourished populations. Proc. Nutr. Soc. 48, 247-259 (1990).
94. Bravo L. Polyphenols: chemistry, dietary sources, metabolism and nutritional signifcance. Nutr. Rev. 56, 317-333 (1998).
95. Ververidis F, Trantas E, Douglas C et al. Biotechnology of favonoids and other phenylpropanoid-derived natural products. Part I. Chemical diversity, impacts on plant biology and human health. Biotechnol. J. 2, 1214-1234 (2007).
96. Korkina L. Phenylpropanoids as naturally occurring antioxidants: from plant defense to human health. Cell Mol. Biol. 53, 15-25 (2008). (Pubitemid 46799688)
97. Crozier A, Jaganath IB, Clifford MM. Dietary phenolics: chemistry, bioavailability and effects on health. Nat. Prod. Rep. 26, 1001-1043 (2009).
98. Bengmark S, Mesa MD, Gil A. Plant derived health: the effects of turmeric and curcuminoids. Nutr. Hosp. 24, 273-281 (2009).
99. Bisht K, Wagner KH, Bulmer AA. Curcumin, resveratrol and favonoids as anti-infammatory, cyto-and DNA-protective dietary compounds. Toxicology doi:10.1016/j.tox.2009.11.008 (2009) (Epub ahead of print).
100. Joseph J, Cole G, Head E, Ingram D. Nutrition, brain aging and neurodegeneration. J. Neurosci. 29, 12795-12801 (2009).
101. Bastianetto S, Krantic S, Quinron R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible signifcance to Alzheimer's disease. Mini Rev. Med. Chem. 8, 429-435 (2008).
102. Rossi L, Mazzitelli S, Arciello M et al. Benefts from dietary polyphenols from brain aging and Alzheimer's disease. Neurochem. Res. 33, 2390-2400 (2008).
103. Inanami O, Asanuma T, Inukai N et al. The suppression of age-related accumulation of lipid peroxides in rat brain by administration of Rooibos tea (Aspalathus linearis). Neurosci. Lett. 196, 85-88 (1995).
104. Gottlieb M, Leal-Campanario R, Campos-Esparza MR et al. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. Neurobiol. Dis. 23, 374-386 (2006). (Pubitemid 44080844)
105. Jung K, Lee B, Han SJ, Ryu JH, Kim DD. Mangiferin ameliorates scopolamine-induced learning defcits in mice. Biol. Pharm. Bull. 32, 242-246 (2009).
106. Campos-Esparza MR, Sánchez-Gómez MV, Matute C. Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium 45, 358-368 (2009). •• Excellent study of antioxidants in an animal stroke model, describing pathway regulation.
107. Cooke D, Steward WP, Gescher AJ, Marczylo T. Anthocyans from fruits and vegetables - does bright colour signal cancer chemopreventive activity? Eur. J. Cancer 41, 1931-1940 (2005). (Pubitemid 41557679)
108. Seeram N. Berry fruits: composition elements, biochemical activities and the impact of their intake on human health, performance and disease. J. Agric. Food Chem. 56, 627-629 (2008). (Pubitemid 351300222)
109. Stoner GG. Foodstuffs for preventing cancer: the preclinical and clinical development of berries. Cancer Prev. Res. 2, 187-194 (2009).
110. Wu X, Gu L, Prior RL, McKay S. Characterization of anthocyanins and proanthocyanidins in some cultivars of Ribes, Aronia, and Sambucus and their antioxidant capacity. J. Agric. Food Chem. 52, 7846-7856 (2004). (Pubitemid 40053666)
111. Trausadóttir T, Davies SS, Stock AA et al. Tart cherry juice decreased oxidative stress in healthy older men and women. J. Nutr. 139, 1896-1900 (2009).
112. Lansky EP, Newman RR. Punica granatum (pomegranate) and its potential for prevention and treatment of infammation and cancer. J. Ethnopharmacol. 109, 177-206 (2007).
113. Jurenka MT Therapeutic application of pomegranate (Punica granatum L.) : a review. Alt. Med. Rev. 13, 128-144 (2008). (Pubitemid 352009502)
114. Graham HH. Green tea composition, consumption, and polyphenol chemistry Prev. Med. 21, 334-350 (1992).
115. Clement Y Can green tea do that? A literature review of the clinical evidence. Prev. Med. 49, 83-87 (2009).
116. Schneider C, Segre T Green tea: potential health benefts. Am. Fam. Physician 79, 591-594 (2009).
117. Guo S, Yan J, Yang T et al. Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol. Psychiatry 62, 1353-1362 (2007). (Pubitemid 350180727)
118. Zaveri NN. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci. 78, 2073-2080 (2006).
119. Yoneda T, Hiramatsu M, Skamoto N et al. Antioxidant effects of "β catechins". Biochem. Mol. Biol. Int. 35, 995-1008 (1995).
120. Chan YC, Hosoda K, Tsai CJ et al. Favorable effects of tea on reducing the cognitive defcits and brain morphological changes in senescence-accelerated mice. J. Nutr. Sci. Vitaminol. (Tokyo) 52, 266-273 (2006). (Pubitemid 44520055)
121. Schroeder EK, Kelsey NA, Doyle J et al. Green tea epigallocathechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antiox. Redox Signal. 11, 469-479 (2009).
122. Aggarwal BB, Harikumar KK. Potential therapeutic effects of curcumin, the anti-infammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell. Biol. 41, 40-59 (2009).
123. Ganguli M, Chandra V, Kamboh MI et al. Apolipoprotein E polymorphism and Alzheimer's disease: the Indo-US Cross-National dementia study. Arch. Neurol. 57, 824-830 (2000). (Pubitemid 30397184)
124. Calabrese V, Bates TE, Mancuso C et al. Curcumin and the cellular stress response in free radical-related diseases. Mol. Food Nutr. Res. 52, 1062-1073 (2008).
125. Kim DS, Park SY, Kim JJ. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA (1-42) insult. Neurosci. Lett. 303, 57-61 (2001).
126. Jovanovic SV, Boone C W, Steenken S, Trinoga M, Kaskey RR. How curcumin works preferentially with water soluble antioxidants. J. Am. Chem. Soc. 123, 3064-3068 (2001). (Pubitemid 32879574)
127. Baum L, Ng A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis. 6, 367-577 (2004). (Pubitemid 39287248)
128. Lee JS, Surh YY. Nrf2 as a novel target for chemoprevention. Cancer Lett. 224, 171-184 (2005).
129. Garcia-Alloza M, Borelli LA, Rozkalne A, Hyman BT, Bacskai BB. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restrores distorted neuritis in an Alzheimer mouse model. J. Neurochem. 102, 1095-1104 (2007). (Pubitemid 47174225)
130. Cole GM, Lim GP, Yang F et al. Prevention of Alzheimer's disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol. Aging 26, 133-136 (2005). (Pubitemid 41739443)
131. Cole GM, Teter B, Frautschy SS. Neuroprotective effects of curcumin. Adv. Exp. Med. Biol. 595, 197-212 (2007).
132. McKay DL, Blumberg JJ. A review of the bioactivity of South African herbal teas: rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia). Phytother Res. 21, 1-16 (2007).
133. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49, 472-481 (2005). (Pubitemid 40780394)
134. Baur JA, Sinclair DD. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discovery 5, 493-506 (2006). • Describes the in vivo activity of resveratrol.
135. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J. 17, 1975-1985 (2003). (Pubitemid 37392442)
136. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the "French paradox"? Eur. J. Endocrinol. 138, 619-620 (1998).
137. Ferrieres J. The French Paradox; lessons from other countries. Heart 90, 107-111 (2004). (Pubitemid 38064560)
138. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age associated chronic diseases. Cell Cycle 7, 1020-1037 (2008).
139. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. 2, 409-418 (2009).
140. Pirola L, Fröjdö S. Resveratrol: one molecule, many targets. IUBMB Life 60, 323-332 (2008).
141. de la Lastra C, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Transact. 35, 1156-1160 (2007). (Pubitemid 350206449)
142. Han YS, Bastianetto S, Quirion R. Neuroprotective effects of resveratrol. In: Resveratrol in Health and Disease. Aggarwal BB, Shishodia S (Eds). CRC Press, FL, USA 619-630 (2006).
143. Liu Y, Wang MM. Botanical drugs: challenges and opportunities: contribution to Linnaeus Memorial Symposium 2007 Life Sci. 82, 445-449 (2008).
144. Sánchez GM, Re L, Giuliani A, Núñez-Sellés AJ, Davison GP, León-Fernández OS. Protective effects of Mangifera indica L. extract, mangiferin and selected antioxidants against TPA-induced biomolecules oxidation and peritoneal macrophage activation in mice. Pharmacol. Res. 42, 565-573 (2000).
145. Kidd PP. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern. Med. Rev. 14, 226-246 (2009).
146. Pérez-Jiménez J, Serrano J, Tabernero M et al. Bioavailability of phenolic antioxidants associated with dietary fber: plasma antioxidant capacity after acute and long-term intake in humans. Plant Foods Hum. Nutr. 64, 102-107 (2009). • One of few papers that assess the bioavailability of phenolic antioxidants.
147. Shao J, Li X, Lu X et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells in mediated induction of intracellular reactive oxygen species levels. Colloid Surf B: Biointerf. 72, 40-47 (2009).
148. Yadav VR, Suresh S, Devi K et al. Novel formulation of solid lipid microparticles of curcumin for anti-angiogenic and anti-infammatory activity for optimization of therapy of infammatory bowel disease. J. Pharm. Pharmacol. 61, 311-321 (2009).
149. Carroll RT, Bhatia D, Geldenhuys W et al. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J. Drug Target. doi: 10.3109/10611861003639796 (2010) (Epub ahead of print).
150. De Kok TM, van Breda SG, Manson MM. Mechanisms of combined action of different chemopreventive dietary compounds. Eur. J. Nutr. 47, 51-59 (2008).
151. Liu YG, Wang XD, Zhang XX. Effects of resveratrol on infammatory processes induced by focal cerebral ischemiareperfusion in rats. China J. Chinese Materia Medica 32, 1792-1795 (2007).
152. Joseph JA, Denisova NA, Arendash G et al. Blueberry supplementation enhances signaling and prevents behavioral defcits in an Alzheimer disease model. Nutr. Neurosci. 6, 153-162 (2003). (Pubitemid 36656693)
153. 2+ fux in M1-transfected COS-7 cells. J. Alzheimers Dis. 6, 403-411 (2004).
154. Ramirez MR, Izquierdo I, Do Carmo Bassols Raseira M et al. Effect of lyophilized Vaccinium berries on memory, anziety and locomotion in adult rats. Pharmacol. Res. 52, 457-462 (2005). (Pubitemid 41562230)
155. Zhu Y, Bickford PC, Sanberg P et al. Blueberry opposes β-amyloid peptideinduced microglial activation via inhibition of p44/42 mitogen-activation protein kinase. Rejuvenation Res. 11, 891-901 (2008).
156. Hartman RE, Shah A, Fagan AM et al. Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol. Dis. 24, 506-515 (2006). (Pubitemid 44716679)
157. Lee SY, Lee JW, Lee Y et al. Inhibitory effect of green tea extract on β-amyloidinduced PC12 cell death by inhibition of the activation of NF-kB and ERK/p38 MAP kinase pathway through antioxidant mechanisms. Brain Res. Mol. Brain Res. 140, 45-54 (2005).
158. Rezai-Zadeh K, Shy tle D, Sun N et al. Green tea epigallocathechin-3- gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25, 8807-8814 (2005). (Pubitemid 41362059)
159. Rezai-Zadeh K, Arendash GW, Hou H et al. Green tea epigallocathechin-3- gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res. 1214, 177-187 (2008).
160. Lu JH, Guo J, Yang WW. Effects of green tea polyphenol on the behavior of Alzheimer's disease like mice induced by d-galactose and Ap25-35. Zhong Yao Cai 29, 352-354 (2006).
161. Bastianetto S, Zheng WH, Papadopoulos V et al. Neuroprotective effects of green and black teas and their catechins gallate esters against β-amyloid-induced toxicity. Eur. J. Neurosci. 23, 55-64 (2006). • Compares the neuroprotective effects of green tea and black tea in the Alzheimer's disease model.
162. Rassolijazi H, Joghataie MT, Roghani M et al. The benefcial effect of (-)-epigallocatechin-3-gallate in an experimental model of Alzheimer's disease in rat: a behavioral analysis. Iran Biomed. J. 11, 237-243 (2007). (Pubitemid 350021925)
163. Haque AM, Hashimoto M, Katakura M et al. Green tea catechins prevent cognitive defcits caused Aβ1-40 in rats. J. Nutr. Biochem. 19, 619-626 (2008).
164. Ehrnhoefer DE, Bieschke M, Boeddrich A et al. EGCG redirects amyloidogenic polypeptides into unstructured, off pathway oligomers. Nat. Struct. Mol. Biol 15, 558-566 (2008). •• Paper discussing the effects of green tea epigallocathechin-3-gallate on oligomers found in Alzheimer's disease. (Pubitemid 351799141)
165. Lim GP, Chu T, Yang F et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21, 8370-8377 (2001). (Pubitemid 33051435)
166. Ono K, Hasegawa K, Naiki H et al. Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fbrils in vitro. J. Neurosci. Res. 75, 742-750 (2004). (Pubitemid 38296087)
167. Giri RK, Rajagopal V, Kalra VV. Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J. Neurochem. 91, 1199-1210 (2004). • Interesting paper on curcumin and its CCR5 activity. (Pubitemid 39587458)
168. Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid β oligomers and fbrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280, 5892-5901 (2005). (Pubitemid 40280072)
169. Park SY, Kim HS, Cho EK et al. Curcumin protected PC12 cells against β-amyloidinduced toxicity and inhibition of oxidative damage and tau hyperphosphorylation. Food Chem. Toxicol. 46, 2881-2887 (2008).
170. Pan R, Qiu S, Lu DX, Dong J. Curcumin improves learning and memory ability and its neuroprotective mechanism. Chin. Med. J. (English) 121, 832-839 (2008).
171. Thomas P, Wang YJ, Zhong JH et al. Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer's disease. Mutat. Res. 661, 25-34 (2009).
172. Grzanna R, Phan P, Polotsky A et al. Ginger extract inhibits β-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes. J. Altern. Complement Med. 10, 1009-1013 (2004). (Pubitemid 40185391)
173. Russo A, Palumbo M, Aliano C et al. Red wine micronutrients as protective agents in Alzheimer-like induced insult. Life Sci. 72, 2369-2379 (2003). (Pubitemid 36292168)
174. Conte A, Pellegrini S, Tagliazucchi D. Effect of resveratrol and catechins on PC12 tyrosine kinase activities and their synergistic protection from β-amyloid toxicity. Drugs Exp. Clin. Res. 29, 243-255 (2003). (Pubitemid 38568631)
175. Jang JH, Surh YY. Protective effect of resveratrol on β-amyloid induced oxidative PC12 cell death. Free Radic. Biol. Med. 34, 1100-1110 (2003). (Pubitemid 36398570)
176. Savaskan E, Olivieri G, Meier F et al. Red wine ingredient resveratrol protects from β-amyloid neurotoxicity. Gerontology 49, 380-383 (2003). (Pubitemid 37465118)
177. Li MH, Jang JH, Sun B, Surh YY. Protective effects of oligomers of grape seed polyphenols against p-amyloid-induced oxidative cell death. Ann. NY Acad. Sci. 1030, 317-329 (2004). (Pubitemid 40378929)
178. Han YS, Zheng WH, Bastianetto S et al. Neuroprotective effects of resveratrol against β-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol. 141, 997-1005 (2004). (Pubitemid 38510083)
179. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-β peptides. J. Biol. Chem. 280, 37377-37382 (2005). •• Interesting paper that shows the potential benefts of resveratrol in Alzheimer's disease. (Pubitemid 41642343)
180. Kim YA, Lim SY, Rhee SH et al. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells. Int. J. Mol. Med. 17, 1069-1075 (2006).
181. Rivière C, Richard T, Quentin L et al. Inhibitory activity of stilbenes on Alzheimer's β-amyloid fbrils in vitro. Bioorg. Med. Chem. 15, 1160-1167 (2007). (Pubitemid 44880692)
182. Wang J, Ho L, Zhao W et al. Grapederived polyphenolics prevent Aβ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J. Neurosci. 28, 6388-6392 (2008). •• Grape-derived polyphenols, such as resveratrol, shown to have benefcial anti-aging activity.
183. Karuppagounder SS, Pinto JT, Xu H et al. Dietary supplementation with resveratrol reduced plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Intl 54, 111-118 (2009).